Early neural signatures of cancer‐related fatigue: A longitudinal magnetic resonance imaging study of cortical micro‐ and macrostructural changes during breast cancer chemotherapy

Cancer · Published 2026-07-28 · DOI 10.1002/cncr.70558

Free full text

Authors (10)

Yanfei Zhou, Jin Liu, Xiao Fu, Jian Fan, Zong Cao, Jing Li, Ruiping Ye, Hongzhi Wang, Lizhuang Yang, Hai Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhou, Y., Liu, J., Fu, X., et al. (2026). Early neural signatures of cancer‐related fatigue: A longitudinal magnetic resonance imaging study of cortical micro‐ and macrostructural changes during breast cancer chemotherapy. Cancer. https://doi.org/10.1002/cncr.70558

Related articles

• New data inform decision‐making for breast cancer surgeries · Cancer · 2026 · Same journal
• DELII: Ultralow‐dose nivolumab extended overall survival after prior systemic therapy · Cancer · 2026 · Same journal
• Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis · Cancer · 2026 · Same journal
• Most older patients with advanced cancer prioritize QOL over extending survival · Cancer · 2026 · Same journal
• Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California · Cancer · 2026 · Same journal
• Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions · Cancer · 2026 · Same journal
• First‐line CDK4/6 inhibitors fail to improve overall survival in advanced breast cancer · Cancer · 2026 · Same journal
• HER2 ‐targeting zongertinib shows early activity in untreated advanced HER2 ‐mutant NSCLC · Cancer · 2026 · Same journal
• EXPRESSION OF CONCERN: Prolyl Hydroxylase‐2 (PHD2) Exerts Tumor‐Suppressive Activity in Pancreatic Cancer† · Cancer · 2026 · Same journal
• Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma · Cancer · 2026 · Same journal